Company news

Scynexis, Inc. news in 2024

Scynexis, Inc.'s news releases, calls and decks from 2024, newest first.

View company

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

December 17, 2024

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 5, 2024

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

October 9, 2024

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

October 2, 2024

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

August 26, 2024

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 7, 2024

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

July 22, 2024

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

April 29, 2024

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

April 8, 2024

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

March 27, 2024

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

January 29, 2024

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

January 28, 2024

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

January 4, 2024

Decks in 2024